[Bone marrow fibrosis during therapy of hairy cell leukemia].
The influence of Cladribin therapy to bone marrow fibrosis in patients with hairy cell leukemia was studied. Eighteen patients were included in the study; bone marrow fibrosis was graded 0-4 according to the quantity and pattern of distribution of reticulin. The grade of bone marrow fibrosis was established before the therapy and then in 12- and 24-month intervals. Patients showed complete remission after the therapy and remarkable reduction of bone marrow fibrosis.
Dĕdic
K
K
Fingerlandův ústav patologie, Lékarská fakulta v Hradci Králové, Univerzita Karlova, Praha. dedic@fnhk.cz
Zák
P
P
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017338:Cladribine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000139:chemically induced* / Q000473:pathology
D000970:Antineoplastic Agents; D017338:Cladribine